Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates May 26, 2026

https://investors.kailera.com/news-releases/news-release-details/kailera-reports-first-quarter-2026-financial-results-and?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--rt-yETpHe7TC-qElm6tCl1MSsQeYQwmmhjO4a73CF98vQ1Kr7Tvpiz1QVnNCfcUzfTTlf03jhoDdvOrr6o4nKjOFpCw&_hsmi=420814327&utm_content=420814327&utm_source=hs_email Kailera's own 'triple-G' drug also looks very powerful Kailera said yesterday that its investigational obesity drug that targets three hormones led to significant weight loss in a Phase 1 study. After 12 weeks, patients who received the highest dose of the weekly injectable drug, called KAI-4729, experienced up to 16% weight loss, while those on placebo lost 5.4% of their weight. That's a really rapid rate of weight loss. For context, Novo Nordisk's Wegovy led to 15% weight loss over 68 weeks in its pivotal trial. (It is notable, though, that the placebo group experienced a higher rate of weight loss than we typically see with placebo groups.) Kailera's drug activates receptors of the GLP-1, GIP, and glucagon hormones. It's similar to Eli Lilly's investigational treatment retatrutide (also known as the “triple-G” drug). Retatrutide has been shown to be very efficacious in Phase 3 studies, but it's also raised concerns about whether the field is pushing patients to lose too much weight loss too quickly. Kailera launched in 2024 with a plan to develop and sell obesity drug candidates from the Chinese company Jiangsu Hengrui Pharmaceuticals. Last month, it raised $625 million when going public. Hengrui ran this latest study in China and Kailera said it will start another Phase 1 trial outside of China this year, with data expected next year.